USD10
ZYME Shares
About ZymeworksZymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
USD10
ZYME Shares
About ZymeworksZymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
Stats
TRADING WINDOW
Closed
OPENS AT
Not enough data
MARKET CAP
$1.75B
OPEN PRICE
$23.80
LOW (1Y)
$9.03
HIGH (1Y)
$28.49
LOW (24H)
$23.29
HIGH (24H)
$24.16
VOLUME (24H)
$604.39K
4.7%
Price history
Time | Price | Change |
|---|---|---|
Today | $23.80 | |
1 Day | $23.32 | |
1 Week | $22.37 | |
1 Month | $22.27 | |
1 Year | $13.05 |